Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
SavvyWire OpSens TAVR guidewire owned by Haemonetics

New 3-in-1 TAVR guidewire capable of hemodynamic measurements, LV pacing impresses cardiologists

The company behind the new technology was recently acquired for approximately $253 million. 

Cardiologist heart

New AFib guidelines include higher recommendations for catheter ablation, LAAO

Cardiologists, electrophysiologists, surgeons and patient representatives all worked together on the updated guidelines, which were published in both the Journal of the American College of Cardiology and Circulation.

The Medtronic Symplicity Spyral Renal Denervation system uses a catheter that curls in the renal artery to place radiofrequency electrodes against the vessel wall to ablate the nerves that control vasodilation, so the artery can be propped in the fully open position.

First US patient treated with Medtronic’s FDA-approved renal denervation system

Interventional cardiologist David Kandzari, MD, performed the procedure just days after the device received full FDA approval. 

Johnson & Johnson acquires medical device company behind new LAA technology for $400M

The deal could also include additional clinical and regulatory milestone payments in the years ahead.

Cardiawave Valvosoft non-invasive ultrasound therapy

Cardiawave’s non-invasive ultrasound therapy impresses cardiologists early on—could it be an alternative to SAVR, TAVR?

While TAVR and SAVR are reliable treatments for calcific aortic stenosis, some patients are not considered for those procedures due to severe comorbidities or a limited life expectancy. This is where the investigational Valvosoft device from Cardiawave enters the equation.

Medtronic Symplicity Spyral renal denervation

FDA approves another renal denervation system for hypertension

This is the second time in a matter of weeks the FDA has approved an RDN system for uncontrolled hypertension. The SCAI issued a statement about this trend, calling it a “game-changer for both interventional cardiology and the treatment of hypertension."

Thumbnail

TAVR linked to favorable outcomes for asymptomatic and minimally symptomatic patients—but is it necessary?

While TAVR is safe for minimally symptomatic patients, questions remain about whether or not it is actually needed. A new analysis in JACC: Cardiovascular Interventions examines this topic in detail.

Ramon Varcoe explains the LIFE-BTK trial for the Abbott Esprit fully bioresobable scaffold at TCT23.

Fully bioresorbable stents boost care for CLI patients in LIFE-BTK trial

Ramon Varcoe, MBBS, co-principal investigator for the LIFE-BTK trial, discussed the results with Cardiovascular Business at TCT 2023. "I can't wait to start using these in my patients. It's going to make a huge difference."

Displaying 289 - 296 of 975
Design by Adaptive Theme